vs
Amneal Pharmaceuticals, Inc.（AMRX）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
罗布乐思的季度营收约是Amneal Pharmaceuticals, Inc.的1.7倍（$1.4B vs $814.3M），Amneal Pharmaceuticals, Inc.净利率更高（4.3% vs -22.3%，领先26.6%），罗布乐思同比增速更快（43.2% vs 11.5%），罗布乐思自由现金流更多（$308.6M vs $108.5M），过去两年罗布乐思的营收复合增速更高（32.9% vs 11.1%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
AMRX vs RBLX — 直观对比
营收规模更大
RBLX
是对方的1.7倍
$814.3M
营收增速更快
RBLX
高出31.7%
11.5%
净利率更高
AMRX
高出26.6%
-22.3%
自由现金流更多
RBLX
多$200.0M
$108.5M
两年增速更快
RBLX
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $1.4B |
| 净利润 | $35.1M | $-316.0M |
| 毛利率 | 36.5% | 77.7% |
| 营业利润率 | 13.8% | -25.3% |
| 净利率 | 4.3% | -22.3% |
| 营收同比 | 11.5% | 43.2% |
| 净利润同比 | 212.9% | -43.9% |
| 每股收益（稀释后） | $0.10 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRBLX
| Q4 25 | $814.3M | $1.4B | ||
| Q3 25 | $784.5M | $1.4B | ||
| Q2 25 | $724.5M | $1.1B | ||
| Q1 25 | $695.4M | $1.0B | ||
| Q4 24 | $730.5M | $988.2M | ||
| Q3 24 | $702.5M | $919.0M | ||
| Q2 24 | $701.8M | $893.5M | ||
| Q1 24 | $659.2M | $801.3M |
净利润AMRXRBLX
| Q4 25 | $35.1M | $-316.0M | ||
| Q3 25 | $2.4M | $-255.6M | ||
| Q2 25 | $22.4M | $-278.4M | ||
| Q1 25 | $12.2M | $-215.1M | ||
| Q4 24 | $-31.1M | $-219.6M | ||
| Q3 24 | $-156.0K | $-239.3M | ||
| Q2 24 | $6.0M | $-205.9M | ||
| Q1 24 | $-91.6M | $-270.6M |
毛利率AMRXRBLX
| Q4 25 | 36.5% | 77.7% | ||
| Q3 25 | 34.9% | 78.2% | ||
| Q2 25 | 39.5% | 78.2% | ||
| Q1 25 | 36.8% | 78.3% | ||
| Q4 24 | 36.0% | 77.9% | ||
| Q3 24 | 38.4% | 77.7% | ||
| Q2 24 | 35.6% | 77.8% | ||
| Q1 24 | 36.1% | 77.7% |
营业利润率AMRXRBLX
| Q4 25 | 13.8% | -25.3% | ||
| Q3 25 | 9.0% | -21.8% | ||
| Q2 25 | 15.4% | -29.8% | ||
| Q1 25 | 14.4% | -24.6% | ||
| Q4 24 | 10.4% | -24.7% | ||
| Q3 24 | 12.6% | -30.4% | ||
| Q2 24 | 13.6% | -26.6% | ||
| Q1 24 | -1.6% | -37.7% |
净利率AMRXRBLX
| Q4 25 | 4.3% | -22.3% | ||
| Q3 25 | 0.3% | -18.8% | ||
| Q2 25 | 3.1% | -25.8% | ||
| Q1 25 | 1.8% | -20.8% | ||
| Q4 24 | -4.3% | -22.2% | ||
| Q3 24 | -0.0% | -26.0% | ||
| Q2 24 | 0.9% | -23.0% | ||
| Q1 24 | -13.9% | -33.8% |
每股收益（稀释后）AMRXRBLX
| Q4 25 | $0.10 | $-0.44 | ||
| Q3 25 | $0.01 | $-0.37 | ||
| Q2 25 | $0.07 | $-0.41 | ||
| Q1 25 | $0.04 | $-0.32 | ||
| Q4 24 | $-0.10 | $-0.32 | ||
| Q3 24 | $0.00 | $-0.37 | ||
| Q2 24 | $0.02 | $-0.32 | ||
| Q1 24 | $-0.30 | $-0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $3.1B |
| 总债务越低越好 | $2.6B | $1.2B |
| 股东权益账面价值 | $-70.8M | $394.5M |
| 总资产 | $3.7B | $9.6B |
| 负债/权益比越低杠杆越低 | — | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资AMRXRBLX
| Q4 25 | $282.0M | $3.1B | ||
| Q3 25 | $201.2M | $2.9B | ||
| Q2 25 | $71.5M | $2.6B | ||
| Q1 25 | $59.2M | $2.7B | ||
| Q4 24 | $110.6M | $2.4B | ||
| Q3 24 | $74.0M | $2.3B | ||
| Q2 24 | $43.8M | $2.4B | ||
| Q1 24 | $46.5M | $2.4B |
总债务AMRXRBLX
| Q4 25 | $2.6B | $1.2B | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | $1.2B | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益AMRXRBLX
| Q4 25 | $-70.8M | $394.5M | ||
| Q3 25 | $-109.5M | $407.6M | ||
| Q2 25 | $-112.1M | $353.2M | ||
| Q1 25 | $-131.7M | $310.7M | ||
| Q4 24 | $-109.3M | $221.4M | ||
| Q3 24 | $-93.4M | $189.9M | ||
| Q2 24 | $-57.5M | $121.5M | ||
| Q1 24 | $-63.7M | $71.6M |
总资产AMRXRBLX
| Q4 25 | $3.7B | $9.6B | ||
| Q3 25 | $3.6B | $8.6B | ||
| Q2 25 | $3.4B | $7.8B | ||
| Q1 25 | $3.4B | $7.5B | ||
| Q4 24 | $3.5B | $7.2B | ||
| Q3 24 | $3.5B | $6.7B | ||
| Q2 24 | $3.5B | $6.5B | ||
| Q1 24 | $3.5B | $6.3B |
负债/权益比AMRXRBLX
| Q4 25 | — | 2.98× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.48× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $607.0M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $308.6M |
| 自由现金流率自由现金流/营收 | 13.3% | 21.8% |
| 资本支出强度资本支出/营收 | 2.7% | 21.1% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $269.9M | $1.4B |
8季度趋势，按日历期对齐
经营现金流AMRXRBLX
| Q4 25 | $130.3M | $607.0M | ||
| Q3 25 | $118.5M | $546.2M | ||
| Q2 25 | $83.8M | $199.3M | ||
| Q1 25 | $7.4M | $443.9M | ||
| Q4 24 | $118.1M | $184.5M | ||
| Q3 24 | $141.8M | $247.4M | ||
| Q2 24 | $39.7M | $151.4M | ||
| Q1 24 | $-4.4M | $238.9M |
自由现金流AMRXRBLX
| Q4 25 | $108.5M | $308.6M | ||
| Q3 25 | $106.2M | $443.6M | ||
| Q2 25 | $61.0M | $176.7M | ||
| Q1 25 | $-5.8M | $426.5M | ||
| Q4 24 | $102.9M | $120.6M | ||
| Q3 24 | $124.8M | $218.0M | ||
| Q2 24 | $29.0M | $111.7M | ||
| Q1 24 | $-13.6M | $192.3M |
自由现金流率AMRXRBLX
| Q4 25 | 13.3% | 21.8% | ||
| Q3 25 | 13.5% | 32.6% | ||
| Q2 25 | 8.4% | 16.3% | ||
| Q1 25 | -0.8% | 41.2% | ||
| Q4 24 | 14.1% | 12.2% | ||
| Q3 24 | 17.8% | 23.7% | ||
| Q2 24 | 4.1% | 12.5% | ||
| Q1 24 | -2.1% | 24.0% |
资本支出强度AMRXRBLX
| Q4 25 | 2.7% | 21.1% | ||
| Q3 25 | 1.6% | 7.5% | ||
| Q2 25 | 3.2% | 2.1% | ||
| Q1 25 | 1.9% | 1.7% | ||
| Q4 24 | 2.1% | 6.5% | ||
| Q3 24 | 2.4% | 3.2% | ||
| Q2 24 | 1.5% | 4.4% | ||
| Q1 24 | 1.4% | 5.8% |
现金转化率AMRXRBLX
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
RBLX
暂无分部数据
